Lexaria Bioscience Corp.
Disclaimer : Sections of this page are auto-generated by Artificial Intelligence and shall not be understood as Investment AdviceThis page was updated : N/A. Premium customers can update this page on demand.
Newsflash
N/A
Based on these articles
- Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
- Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery
- Lexaria Bioscience Announces Closing of $2.0 Million Public Offering
- cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial
- Lexaria Announces 2023 Annual Meeting Results
- Why Is Lexaria Bioscience (LEXX) Stock Down 27% Today?
- Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering
Business Overview
N/A
Yahoo - Business Overview
Lexaria Bioscience Corp. operates as a biotechnology company. The company develops and out-licenses its DehydraTECH combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. Its DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, ...
Flags & Key Risks
Negative profit margins
Negative EV to Ebitda
Negative Return on Equity
Negative Debt Trend
Negative Revenue Trend
Pre-market negative on higher volumes
News Coverage
| No research found for |
23 days ago @10-Q
10-Q - Periodic Financial Reports |
#LEXX #regulatory filing #periodic #reports #financial #LEXX |
| No lawsuits found for |
Offcanvas top
Placeholder
Offcanvas left
Placeholder
Loading...
Offcanvas bottom
Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists,
etc.